<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00557193</url>
  </required_header>
  <id_info>
    <org_study_id>AALL0631</org_study_id>
    <secondary_id>NCI-2009-00313</secondary_id>
    <secondary_id>COG-AALL0631</secondary_id>
    <secondary_id>08-146</secondary_id>
    <secondary_id>CDR0000573996</secondary_id>
    <secondary_id>AALL0631</secondary_id>
    <secondary_id>AALL0631</secondary_id>
    <secondary_id>U10CA180886</secondary_id>
    <secondary_id>U10CA098543</secondary_id>
    <nct_id>NCT00557193</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia</brief_title>
  <official_title>A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; NSC#617807)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase III trial studies combination chemotherapy with or without lestaurtinib with to
      see how well they work in treating younger patients with newly diagnosed acute lymphoblastic
      leukemia. Drugs used in chemotherapy work in different ways to stop the growth of stop cancer
      cells, either by killing the cells, by stopping them from dividing, or by stopping them from
      spreading. Lestaurtinib may stop the growth of cancer cells by blocking some of the enzymes
      needed for cell growth. It is not yet known whether combination chemotherapy is more
      effective with or without lestaurtinib in treating acute lymphoblastic leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To estimate the 3-year event-free survival (EFS) of infants with mixed lineage
      leukemia-rearranged (MLL-R) acute lymphoblastic leukemia (ALL) treated with chemotherapy plus
      the fms-related tyrosine kinase 3 (FLT3) inhibitor lestaurtinib.

      SECONDARY OBJECTIVES:

      I. To compare the 3-year EFS of infants with MLL-R ALL treated with chemotherapy plus the
      FLT3 inhibitor lestaurtinib to MLL-R patients treated with chemotherapy alone.

      II. To determine a safe, tolerable and biologically active dose of lestaurtinib given in
      sequential combination with chemotherapy in MLL-R infants.

      III. To characterize the pharmacokinetics and pharmacodynamics of lestaurtinib in infants
      when given at the proposed dose in sequential combination with chemotherapy.

      IV. To identify molecular mechanisms of resistance to lestaurtinib in leukemic blasts.

      V. To describe levels of minimal residual disease in infants with ALL within the context of
      the proposed therapy, and correlate with outcome.

      VI. To identify gene expression patterns in diagnostic infant leukemia samples that correlate
      with outcome within the context of the proposed therapy.

      VII. To describe the outcome of infants with MLL-G ALL treated with a modified P9407
      chemotherapy backbone that includes an extended continuation phase.

      OUTLINE:

      INDUCTION THERAPY (WEEKS 1-5): All patients receive induction therapy comprising vincristine
      sulfate intravenously (IV) over 1 minute on days 8, 15, 22, and 29; daunorubicin
      hydrochloride IV over 30 minutes on days 8 and 9; cyclophosphamide IV over 30 minutes every
      12 hours on days 3 and 4 (closed as of 05/19/09); pegaspargase or asparaginase
      intramuscularly (IM) on days 15, 18, 22, 25, 29, and 33; prednisone orally (PO) thrice daily
      (TID) or methylprednisolone IV on days 1-7; dexamethasone IV or PO TID on days 8-28;
      cytarabine IV over 30 minutes on days 8-21; methotrexate intrathecally (IT) on days 1 and 29;
      cytarabine IT on day 15; hydrocortisone IT on days 15 and 29; and filgrastim IV or
      subcutaneously (SC) beginning on day 5 and continuing until blood counts recover.
      Standard-risk patients are non-randomly assigned to receive a less intensive chemotherapy
      regimen without lestaurtinib (post-induction therapy A).

      POST-INDUCTION THERAPY A: (for standard-risk patients MLL-germline [G])

      INDUCTION INTENSIFICATION (WEEKS 6-9): Patients receive high-dose methotrexate IV
      continuously over 24 hours on days 1 and 8; triple IT chemotherapy comprising methotrexate,
      cytarabine, and hydrocortisone on days 1 and 8; leucovorin calcium IV or PO every 6 hours
      beginning 42 hours after start of high-dose methotrexate and continuing until methotrexate
      level is &lt; 0.1 uM; cyclophosphamide IV over 30 minutes on days 15-19; etoposide IV over 2
      hours on days 15-19; and filgrastim IV or SC beginning on day 20 and continuing until blood
      counts recover. Patients in morphologic remission proceed to re-induction therapy.

      RE-INDUCTION (WEEKS 10-12): Patients receive vincristine sulfate IV over 1 minute on days 1,
      8, and 15; daunorubicin hydrochloride IV over 30 minutes on days 1 and 2; cyclophosphamide IV
      over 30 minutes every 12 hours on days 3 and 4; pegaspargase or asparaginase IM on day 4;
      dexamethasone IV or PO twice daily (BID) on days 1-7 and 15-21; triple IT chemotherapy
      comprising methotrexate, cytarabine, and hydrocortisone on days 1 and 15; and filgrastim IV
      or SC beginning on day 5 and continuing until blood counts recover.

      CONSOLIDATION (WEEKS 13-19): Patients receive high-dose methotrexate IV continuously over 24
      hours on days 1 and 8; leucovorin calcium IV every 6 hours beginning 42 hours after start of
      high-dose methotrexate and continuing until methotrexate level is &lt; 0.1 uM; triple IT
      chemotherapy comprising methotrexate, cytarabine, and hydrocortisone on day 1; etoposide IV
      over 2 hours on days 15-19; cyclophosphamide IV over 30 minutes on days 15-19; high-dose
      cytarabine IV over 3 hours every 12 hours on days 29 and 30; pegaspargase or asparaginase IM
      on day 30; and filgrastim IV or SC beginning on day 20 and day 31 and continuing until blood
      counts recover.

      CONTINUATION I (WEEKS 20-41): Patients receive vincristine sulfate IV on day 1 in weeks 20
      and 24; dexamethasone IV or PO BID on days 1-5 in weeks 20, and 24; triple IT chemotherapy
      comprising methotrexate, cytarabine, and hydrocortisone on day 1 in weeks 20 and 24;
      methotrexate IV on day 1 in weeks 21-24 and 25-27; etoposide IV over 2 hours on day 1-5 in
      week 28; cyclophosphamide IV over 30 minutes on days 1-5 in week 28; mercaptopurine PO on
      days 1-7 in weeks 21-23 and 25-27; and filgrastim SC or IV beginning on day 6 in week 28 and
      continuing until blood counts recover.

      CONTINUATION II (WEEKS 42-104): Patients receive vincristine sulfate IV on days 1, 29, and
      57; dexamethasone IV or PO BID on days 1-5, 29-33, and 57-61; methotrexate IT on day 1;
      methotrexate PO on days 8, 15, 22, 36, 43, 50, 64, 71, and 78; and mercaptopurine PO on days
      8-28, 36-56, and 64-84. Treatment repeats every 12 weeks for 2 years from diagnosis.

      A safety/activity phase is conducted separately for the intermediate-risk (IR) and high-risk
      (HR) patients to identify a safe, tolerable, and biologically active dose of lestaurtinib
      combined with chemotherapy backbone. Once a tolerable/active dose of lestaurtinib has been
      identified for IR patients, subsequent IR patients are eligible to proceed to an efficacy
      phase, where they are randomized (or non-randomly assigned as of 7/16/2014) to chemotherapy
      with or without lestaurtinib. HR patients separately proceed to the randomized efficacy phase
      if a tolerable/active dose is identified for the HR stratum. IR and HR patients are
      randomized (or non-randomly assigned as of 7/16/2014) to 1 of 2 post-induction therapy
      regimens (post-induction therapy B or C).

      POST-INDUCTION THERAPY B: (chemotherapy only for IR/HR patients classified as MLL-R; age &gt;=
      90 days at diagnosis):

      INDUCTION INTENSIFICATION (WEEKS 6-9): Patients receive high-dose methotrexate, leucovorin
      calcium, cyclophosphamide, etoposide, and filgrastim as in post-induction therapy A induction
      intensification. Patients in morphologic remission proceed to re-induction. (Retired as of
      7/16/2014)

      RE-INDUCTION (WEEKS 10-12): Patients receive vincristine sulfate, daunorubicin hydrochloride,
      cyclophosphamide, pegaspargase or asparaginase, dexamethasone, triple IT chemotherapy, and
      filgrastim as in post-induction therapy A re-induction. (Retired as of 7/16/2014)

      CONSOLIDATION (WEEKS 13-19): Patients receive high-dose methotrexate, leucovorin calcium,
      triple IT chemotherapy, etoposide, cyclophosphamide, high-dose cytarabine, pegaspargase or
      asparaginase, and filgrastim as in post-induction therapy A consolidation. (Retired as of
      7/16/2014)

      CONTINUATION I (WEEKS 20-49): Patients receive vincristine sulfate IV over 1 minute on day 1
      in weeks 20, 24, 33, 37, and 46; dexamethasone PO or IV BID on days 1-5 in weeks 20, 24, 33,
      37, and 46; triple IT chemotherapy on day 1 in weeks 20, 24, 33, 37, and 46; methotrexate IV
      on day 1 in weeks 21-23, 25-26 and 37-45; mercaptopurine PO on days 1-7 in weeks 21-23, 25-26
      and 37-45; etoposide IV over 2 hours on days 1-5 in week 27; cyclophosphamide IV over 2 hours
      on days 1-5 in week 27: high-dose cytarabine IV over 3 hours every 12 hours on days 1 and 2
      in week 30; pegaspargase or asparaginase IM on day 2 in week 30: and filgrastim SC or IV
      beginning on day 3 in weeks 30 and continuing until blood counts recover. (Retired as of
      7/16/2014)

      CONTINUATION II (WEEKS 50-104): Patients receive vincristine sulfate, dexamethasone, IT
      methotrexate, methotrexate PO, and mercaptopurine PO as in post-induction therapy A
      continuation II. Treatment repeats every 12 weeks for 2 years from diagnosis. (Retired as of
      7/16/2014)

      POST-INDUCTION THERAPY C: (chemotherapy and lestaurtinib for IR/HR patients classified as
      MLL-R; age &lt; 90 days at diagnosis)

      INDUCTION INTENSIFICATION THERAPY (WEEKS 6-9): Patients receive high-dose methotrexate,
      leucovorin calcium, cyclophosphamide, etoposide, and filgrastim as in post-induction therapy
      B induction intensification. Patients also receive lestaurtinib PO BID on days 20-27.
      Patients in morphologic remission proceed to re-induction.

      RE-INDUCTION (WEEKS 10-12): Patients receive vincristine sulfate, daunorubicin hydrochloride,
      cyclophosphamide, pegaspargase or asparaginase, dexamethasone, triple IT chemotherapy, and
      filgrastim as in post-induction therapy B re-induction. Patients also receive lestaurtinib PO
      on days 5-20.

      CONSOLIDATION (WEEKS 13-19) Patients receive high-dose methotrexate, leucovorin calcium,
      triple IT chemotherapy, etoposide, cyclophosphamide, high-dose cytarabine, pegaspargase or
      asparaginase, and filgrastim as in post-induction therapy B consolidation. Patients also
      receive lestaurtinib PO on days 20-27 and 31-42.

      CONTINUATION I (WEEKS 20-49): Patients receive vincristine sulfate, dexamethasone, triple IT
      chemotherapy, methotrexate, mercaptopurine, etoposide, high-dose cytarabine, pegaspargase or
      asparaginase, and filgrastim as in post-induction therapy B continuation I. Patients also
      receive lestaurtinib PO on days 2-6 in weeks 20 and 24; days 27-41 in weeks 27-29; days 45-56
      in weeks 30-32.

      CONTINUATION II (WEEKS 50-104): Patients receive vincristine sulfate, dexamethasone, IT
      methotrexate, methotrexate PO, and mercaptopurine PO as in post-induction therapy B
      continuation II. Treatment repeats every 12 weeks for 2 years from diagnosis.

      After completion of study treatment, all patients are followed up every 1-6 months for 4
      years and then annually thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 14, 2008</start_date>
  <primary_completion_date type="Actual">September 30, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Probability for Event-free Survival (EFS) for Patients on Arm C at Dose Level 2 (DL2)</measure>
    <time_frame>From start of post-induction therapy for up to 10 years</time_frame>
    <description>EFS time is defined as time from randomization to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. EFS is constructed using the Kaplan-Meier life table method with confidence interval based on standard errors computed using the method of Peto and Peto.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Probability for Event-free Survival (EFS) of MLL-R Infants Treated With Combination Chemotherapy With or Without Lestaurtinib at DL2</measure>
    <time_frame>From start of post-induction therapy for up to 10 years.</time_frame>
    <description>Event Free Probability where EFS time is defined as time from randomization to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. EFS is constructed using the Kaplan-Meier life table method with confidence interval based on standard errors computed using the method of Peto and Peto. EFS will be compared between patients on treatment Arm C at DL2 to those on Arm B.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Experienced Lestaurtinib-related Dose Limiting Toxicity (DLT)</measure>
    <time_frame>Up to 12 weeks from start of induction</time_frame>
    <description>Lestaurtinib-related dose-limiting toxicity proportions, as measured by NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, will by summarized by dose level for Safety phase patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic AGP Levels in Infants Given Lestaurtinib at DL2 in Combination With Chemotherapy</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Pharmacokinetic AGP levels in infants given lestaurtinib at DL2 in combination with chemotherapy will be described with mean and standard deviation for those with available data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Albumin in Infants Given Lestaurtinib at DL2 in Combination With Chemotherapy</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Pharmacokinetic albumin in infants given lestaurtinib at DL2 in combination with chemotherapy will be described with mean and standard deviation for those with available data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics PIA Levels in Infants Given Lestaurtinib at DL2 in Combination With Chemotherapy</measure>
    <time_frame>Sampled between weeks 6-12 from start of induction</time_frame>
    <description>Summarized with mean and standard deviation for those with available data in Arm C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Describe FLT3 Protein Expression as a Molecular Mechanism of Primary Resistance to Lestaurtinib in Leukemic Blasts</measure>
    <time_frame>Sampled at the start of induction</time_frame>
    <description>Described via mean and standard deviation by group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Describe FLT3 Protein Expression as a Molecular Mechanism of Acquired Resistance to Lestaurtinib in Leukemic Blasts</measure>
    <time_frame>At relapse (up to 3 years)</time_frame>
    <description>Described via means and standard deviations in available Arm C relapse samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Describe in Vitro Sensitivity as a Molecular Mechanism of Primary Resistance to Lestaurtinib in Leukemic Blasts</measure>
    <time_frame>Sampled at the start of induction</time_frame>
    <description>Described via means and standard deviations in samples which have primary resistance to lestaurtinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Describe in Vitro Sensitivity as a Molecular Mechanism of Acquired Resistance to Lestaurtinib in Leukemic Blasts</measure>
    <time_frame>At relapse (up to 3 years)</time_frame>
    <description>Described via means and standard deviations in samples which have acquired resistance to lestaurtinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Probability of Event Free Survival (EFS) by MRD Status and Treatment Arm</measure>
    <time_frame>3 Years from end of Induction)</time_frame>
    <description>Three-year EFS estimates and 90% CI will be reported by treatment arm and end-induction MRD status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identification of Gene Expression Patterns in Diagnostic Infant Leukemia Samples That Correlate With Survival Outcomes</measure>
    <time_frame>At 3 years</time_frame>
    <description>EFS outcomes will be reported by genotype.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identification of Gene Expression Patterns in Diagnostic Infant Leukemia Samples That Correlate With PIA Values</measure>
    <time_frame>At 3 years</time_frame>
    <description>Means and standard deviations of Plasma Inhibitory Activity (PIA) will be given by genotype</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Probability for Event-free Survival (EFS) for Patients on Arm A</measure>
    <time_frame>From start of post-induction therapy for up to 10 years</time_frame>
    <description>EFS time is defined as time from treatment assignment to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. EFS is constructed using the Kaplan-Meier life table method with confidence interval based on standard errors computed using the method of Peto and Peto.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">218</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Acute Undifferentiated Leukemia</condition>
  <condition>Childhood T Acute Lymphoblastic Leukemia</condition>
  <condition>Untreated Childhood Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Arm A (standard risk MLL-G)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Population Description: Eligible patients with MLL-G (germline, or non-rearranged)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (IR/HR MLL-R chemotherapy)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Population Description: Eligible patients with MLL-R (rearranged). Considered Intermediate Risk (IR) if age &gt;= 90 days at diagnosis and High Risk (HR) if age &lt; 90 days at diagnosis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C (IR/HR MLL-R chemotherapy and lestaurtinib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Population Description: Eligible patients with MLL-R (rearranged). Considered Intermediate Risk (IR) if age &gt;= 90 days at diagnosis and High Risk (HR) if age &lt; 90 days at diagnosis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asparaginase</intervention_name>
    <description>Given IV, IM, or PO</description>
    <arm_group_label>Arm A (standard risk MLL-G)</arm_group_label>
    <arm_group_label>Arm B (IR/HR MLL-R chemotherapy)</arm_group_label>
    <arm_group_label>Arm C (IR/HR MLL-R chemotherapy and lestaurtinib)</arm_group_label>
    <other_name>ASP-1</other_name>
    <other_name>Asparaginase II</other_name>
    <other_name>Asparaginase-E.Coli</other_name>
    <other_name>Colaspase</other_name>
    <other_name>Elspar</other_name>
    <other_name>Kidrolase</other_name>
    <other_name>L-Asnase</other_name>
    <other_name>L-ASP</other_name>
    <other_name>L-Asparaginase</other_name>
    <other_name>L-Asparagine amidohydrolase</other_name>
    <other_name>Laspar</other_name>
    <other_name>Lcf-ASP</other_name>
    <other_name>Leucogen</other_name>
    <other_name>Leunase</other_name>
    <other_name>MK-965</other_name>
    <other_name>Paronal</other_name>
    <other_name>Re-82-TAD-15</other_name>
    <other_name>Serasa</other_name>
    <other_name>Spectrila</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (standard risk MLL-G)</arm_group_label>
    <arm_group_label>Arm B (IR/HR MLL-R chemotherapy)</arm_group_label>
    <arm_group_label>Arm C (IR/HR MLL-R chemotherapy and lestaurtinib)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Given IV or IT</description>
    <arm_group_label>Arm A (standard risk MLL-G)</arm_group_label>
    <arm_group_label>Arm B (IR/HR MLL-R chemotherapy)</arm_group_label>
    <arm_group_label>Arm C (IR/HR MLL-R chemotherapy and lestaurtinib)</arm_group_label>
    <other_name>.beta.-Cytosine arabinoside</other_name>
    <other_name>1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-Beta-D-arabinofuranosylcytosine</other_name>
    <other_name>1.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-</other_name>
    <other_name>Alexan</other_name>
    <other_name>Ara-C</other_name>
    <other_name>ARA-cell</other_name>
    <other_name>Arabine</other_name>
    <other_name>Arabinofuranosylcytosine</other_name>
    <other_name>Arabinosylcytosine</other_name>
    <other_name>Aracytidine</other_name>
    <other_name>Aracytin</other_name>
    <other_name>Aracytine</other_name>
    <other_name>Beta-cytosine Arabinoside</other_name>
    <other_name>CHX-3311</other_name>
    <other_name>Cytarabinum</other_name>
    <other_name>Cytarbel</other_name>
    <other_name>Cytosar</other_name>
    <other_name>Cytosine Arabinoside</other_name>
    <other_name>Cytosine-.beta.-arabinoside</other_name>
    <other_name>Cytosine-beta-arabinoside</other_name>
    <other_name>Erpalfa</other_name>
    <other_name>Starasid</other_name>
    <other_name>Tarabine PFS</other_name>
    <other_name>U 19920</other_name>
    <other_name>U-19920</other_name>
    <other_name>Udicil</other_name>
    <other_name>WR-28453</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daunorubicin Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (standard risk MLL-G)</arm_group_label>
    <arm_group_label>Arm B (IR/HR MLL-R chemotherapy)</arm_group_label>
    <arm_group_label>Arm C (IR/HR MLL-R chemotherapy and lestaurtinib)</arm_group_label>
    <other_name>Cerubidin</other_name>
    <other_name>Cerubidine</other_name>
    <other_name>Cloridrato de Daunorubicina</other_name>
    <other_name>Daunoblastin</other_name>
    <other_name>Daunoblastina</other_name>
    <other_name>Daunoblastine</other_name>
    <other_name>Daunomycin Hydrochloride</other_name>
    <other_name>Daunomycin, hydrochloride</other_name>
    <other_name>Daunorubicin.HCl</other_name>
    <other_name>Daunorubicini Hydrochloridum</other_name>
    <other_name>FI-6339</other_name>
    <other_name>Ondena</other_name>
    <other_name>RP-13057</other_name>
    <other_name>Rubidomycin Hydrochloride</other_name>
    <other_name>Rubilem</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Arm A (standard risk MLL-G)</arm_group_label>
    <arm_group_label>Arm B (IR/HR MLL-R chemotherapy)</arm_group_label>
    <arm_group_label>Arm C (IR/HR MLL-R chemotherapy and lestaurtinib)</arm_group_label>
    <other_name>Aacidexam</other_name>
    <other_name>Adexone</other_name>
    <other_name>Aknichthol Dexa</other_name>
    <other_name>Alba-Dex</other_name>
    <other_name>Alin</other_name>
    <other_name>Alin Depot</other_name>
    <other_name>Alin Oftalmico</other_name>
    <other_name>Amplidermis</other_name>
    <other_name>Anemul mono</other_name>
    <other_name>Auricularum</other_name>
    <other_name>Auxiloson</other_name>
    <other_name>Baycuten</other_name>
    <other_name>Baycuten N</other_name>
    <other_name>Cortidexason</other_name>
    <other_name>Cortisumman</other_name>
    <other_name>Decacort</other_name>
    <other_name>Decadrol</other_name>
    <other_name>Decadron</other_name>
    <other_name>Decalix</other_name>
    <other_name>Decameth</other_name>
    <other_name>Decasone R.p.</other_name>
    <other_name>Dectancyl</other_name>
    <other_name>Dekacort</other_name>
    <other_name>Deltafluorene</other_name>
    <other_name>Deronil</other_name>
    <other_name>Desamethasone</other_name>
    <other_name>Desameton</other_name>
    <other_name>Dexa-Mamallet</other_name>
    <other_name>Dexa-Rhinosan</other_name>
    <other_name>Dexa-Scheroson</other_name>
    <other_name>Dexa-sine</other_name>
    <other_name>Dexacortal</other_name>
    <other_name>Dexacortin</other_name>
    <other_name>Dexafarma</other_name>
    <other_name>Dexafluorene</other_name>
    <other_name>Dexalocal</other_name>
    <other_name>Dexamecortin</other_name>
    <other_name>Dexameth</other_name>
    <other_name>Dexamethasonum</other_name>
    <other_name>Dexamonozon</other_name>
    <other_name>Dexapos</other_name>
    <other_name>Dexinoral</other_name>
    <other_name>Dexone</other_name>
    <other_name>Dinormon</other_name>
    <other_name>Fluorodelta</other_name>
    <other_name>Fortecortin</other_name>
    <other_name>Gammacorten</other_name>
    <other_name>Hexadecadrol</other_name>
    <other_name>Hexadrol</other_name>
    <other_name>Lokalison-F</other_name>
    <other_name>Loverine</other_name>
    <other_name>Methylfluorprednisolone</other_name>
    <other_name>Millicorten</other_name>
    <other_name>Mymethasone</other_name>
    <other_name>Orgadrone</other_name>
    <other_name>Spersadex</other_name>
    <other_name>Visumetazone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (standard risk MLL-G)</arm_group_label>
    <arm_group_label>Arm B (IR/HR MLL-R chemotherapy)</arm_group_label>
    <arm_group_label>Arm C (IR/HR MLL-R chemotherapy and lestaurtinib)</arm_group_label>
    <other_name>Demethyl Epipodophyllotoxin Ethylidine Glucoside</other_name>
    <other_name>EPEG</other_name>
    <other_name>Lastet</other_name>
    <other_name>Toposar</other_name>
    <other_name>Vepesid</other_name>
    <other_name>VP 16-213</other_name>
    <other_name>VP-16</other_name>
    <other_name>VP-16-213</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <description>Given IV or SC</description>
    <arm_group_label>Arm A (standard risk MLL-G)</arm_group_label>
    <arm_group_label>Arm B (IR/HR MLL-R chemotherapy)</arm_group_label>
    <arm_group_label>Arm C (IR/HR MLL-R chemotherapy and lestaurtinib)</arm_group_label>
    <other_name>FILGRASTIM, LICENSE HOLDER UNSPECIFIED</other_name>
    <other_name>G-CSF</other_name>
    <other_name>Neupogen</other_name>
    <other_name>r-metHuG-CSF</other_name>
    <other_name>Recombinant Methionyl Human Granulocyte Colony Stimulating Factor</other_name>
    <other_name>rG-CSF</other_name>
    <other_name>Tevagrastim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm A (standard risk MLL-G)</arm_group_label>
    <arm_group_label>Arm B (IR/HR MLL-R chemotherapy)</arm_group_label>
    <arm_group_label>Arm C (IR/HR MLL-R chemotherapy and lestaurtinib)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lestaurtinib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm C (IR/HR MLL-R chemotherapy and lestaurtinib)</arm_group_label>
    <other_name>CEP-701</other_name>
    <other_name>KT-5555</other_name>
    <other_name>SPM-924</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin Calcium</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (standard risk MLL-G)</arm_group_label>
    <arm_group_label>Arm B (IR/HR MLL-R chemotherapy)</arm_group_label>
    <arm_group_label>Arm C (IR/HR MLL-R chemotherapy and lestaurtinib)</arm_group_label>
    <other_name>Adinepar</other_name>
    <other_name>Calcifolin</other_name>
    <other_name>Calcium (6S)-Folinate</other_name>
    <other_name>Calcium Folinate</other_name>
    <other_name>Calcium Leucovorin</other_name>
    <other_name>Calfolex</other_name>
    <other_name>Calinat</other_name>
    <other_name>Cehafolin</other_name>
    <other_name>Citofolin</other_name>
    <other_name>Citrec</other_name>
    <other_name>citrovorum factor</other_name>
    <other_name>Cromatonbic Folinico</other_name>
    <other_name>Dalisol</other_name>
    <other_name>Disintox</other_name>
    <other_name>Divical</other_name>
    <other_name>Ecofol</other_name>
    <other_name>Emovis</other_name>
    <other_name>Factor, Citrovorum</other_name>
    <other_name>Flynoken A</other_name>
    <other_name>Folaren</other_name>
    <other_name>Folaxin</other_name>
    <other_name>FOLI-cell</other_name>
    <other_name>Foliben</other_name>
    <other_name>Folidan</other_name>
    <other_name>Folidar</other_name>
    <other_name>Folinac</other_name>
    <other_name>Folinate Calcium</other_name>
    <other_name>folinic acid</other_name>
    <other_name>Folinic Acid Calcium Salt Pentahydrate</other_name>
    <other_name>Folinoral</other_name>
    <other_name>Folinvit</other_name>
    <other_name>Foliplus</other_name>
    <other_name>Folix</other_name>
    <other_name>Imo</other_name>
    <other_name>Lederfolat</other_name>
    <other_name>Lederfolin</other_name>
    <other_name>Leucosar</other_name>
    <other_name>leucovorin</other_name>
    <other_name>Rescufolin</other_name>
    <other_name>Rescuvolin</other_name>
    <other_name>Tonofolin</other_name>
    <other_name>Wellcovorin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mercaptopurine</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm A (standard risk MLL-G)</arm_group_label>
    <arm_group_label>Arm B (IR/HR MLL-R chemotherapy)</arm_group_label>
    <arm_group_label>Arm C (IR/HR MLL-R chemotherapy and lestaurtinib)</arm_group_label>
    <other_name>3H-Purine-6-thiol</other_name>
    <other_name>6 MP</other_name>
    <other_name>6 Thiohypoxanthine</other_name>
    <other_name>6 Thiopurine</other_name>
    <other_name>6-Mercaptopurine</other_name>
    <other_name>6-Mercaptopurine Monohydrate</other_name>
    <other_name>6-MP</other_name>
    <other_name>6-Purinethiol</other_name>
    <other_name>6-Thiopurine</other_name>
    <other_name>6-Thioxopurine</other_name>
    <other_name>6H-Purine-6-thione, 1,7-dihydro- (9CI)</other_name>
    <other_name>7-Mercapto-1,3,4,6-tetrazaindene</other_name>
    <other_name>Alti-Mercaptopurine</other_name>
    <other_name>Azathiopurine</other_name>
    <other_name>BW 57-323H</other_name>
    <other_name>Flocofil</other_name>
    <other_name>Ismipur</other_name>
    <other_name>Leukerin</other_name>
    <other_name>Leupurin</other_name>
    <other_name>Mercaleukim</other_name>
    <other_name>Mercaleukin</other_name>
    <other_name>Mercaptina</other_name>
    <other_name>Mercaptopurinum</other_name>
    <other_name>Mercapurin</other_name>
    <other_name>Mern</other_name>
    <other_name>NCI-C04886</other_name>
    <other_name>Puri-Nethol</other_name>
    <other_name>Purimethol</other_name>
    <other_name>Purine, 6-mercapto-</other_name>
    <other_name>Purine-6-thiol (8CI)</other_name>
    <other_name>Purine-6-thiol, monohydrate</other_name>
    <other_name>Purinethiol</other_name>
    <other_name>Purinethol</other_name>
    <other_name>U-4748</other_name>
    <other_name>WR-2785</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Given IV, IT, or PO</description>
    <arm_group_label>Arm A (standard risk MLL-G)</arm_group_label>
    <arm_group_label>Arm B (IR/HR MLL-R chemotherapy)</arm_group_label>
    <arm_group_label>Arm C (IR/HR MLL-R chemotherapy and lestaurtinib)</arm_group_label>
    <other_name>Abitrexate</other_name>
    <other_name>Alpha-Methopterin</other_name>
    <other_name>Amethopterin</other_name>
    <other_name>Brimexate</other_name>
    <other_name>CL 14377</other_name>
    <other_name>CL-14377</other_name>
    <other_name>Emtexate</other_name>
    <other_name>Emthexat</other_name>
    <other_name>Emthexate</other_name>
    <other_name>Farmitrexat</other_name>
    <other_name>Fauldexato</other_name>
    <other_name>Folex</other_name>
    <other_name>Folex PFS</other_name>
    <other_name>Lantarel</other_name>
    <other_name>Ledertrexate</other_name>
    <other_name>Lumexon</other_name>
    <other_name>Maxtrex</other_name>
    <other_name>Medsatrexate</other_name>
    <other_name>Metex</other_name>
    <other_name>Methoblastin</other_name>
    <other_name>Methotrexate LPF</other_name>
    <other_name>Methotrexate Methylaminopterin</other_name>
    <other_name>Methotrexatum</other_name>
    <other_name>Metotrexato</other_name>
    <other_name>Metrotex</other_name>
    <other_name>Mexate</other_name>
    <other_name>Mexate-AQ</other_name>
    <other_name>MTX</other_name>
    <other_name>Novatrex</other_name>
    <other_name>Rheumatrex</other_name>
    <other_name>Texate</other_name>
    <other_name>Tremetex</other_name>
    <other_name>Trexeron</other_name>
    <other_name>Trixilem</other_name>
    <other_name>WR-19039</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (standard risk MLL-G)</arm_group_label>
    <arm_group_label>Arm B (IR/HR MLL-R chemotherapy)</arm_group_label>
    <arm_group_label>Arm C (IR/HR MLL-R chemotherapy and lestaurtinib)</arm_group_label>
    <other_name>Adlone</other_name>
    <other_name>Caberdelta M</other_name>
    <other_name>DepMedalone</other_name>
    <other_name>Depo Moderin</other_name>
    <other_name>Depo-Nisolone</other_name>
    <other_name>Duralone</other_name>
    <other_name>Emmetipi</other_name>
    <other_name>Esametone</other_name>
    <other_name>Firmacort</other_name>
    <other_name>Medlone 21</other_name>
    <other_name>Medrate</other_name>
    <other_name>Medrol</other_name>
    <other_name>Medrol Veriderm</other_name>
    <other_name>Medrone</other_name>
    <other_name>Mega-Star</other_name>
    <other_name>Meprolone</other_name>
    <other_name>Methylprednisolonum</other_name>
    <other_name>Metilbetasone Solubile</other_name>
    <other_name>Metrocort</other_name>
    <other_name>Metypresol</other_name>
    <other_name>Metysolon</other_name>
    <other_name>Predni-M-Tablinen</other_name>
    <other_name>Prednilen</other_name>
    <other_name>Radilem</other_name>
    <other_name>Sieropresol</other_name>
    <other_name>Solpredone</other_name>
    <other_name>Summicort</other_name>
    <other_name>Urbason</other_name>
    <other_name>Veriderm Medrol</other_name>
    <other_name>Wyacort</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegaspargase</intervention_name>
    <description>Given IM</description>
    <arm_group_label>Arm A (standard risk MLL-G)</arm_group_label>
    <arm_group_label>Arm B (IR/HR MLL-R chemotherapy)</arm_group_label>
    <arm_group_label>Arm C (IR/HR MLL-R chemotherapy and lestaurtinib)</arm_group_label>
    <other_name>L-Asparaginase with Polyethylene Glycol</other_name>
    <other_name>Oncaspar</other_name>
    <other_name>PEG-Asparaginase</other_name>
    <other_name>PEG-L-Asparaginase</other_name>
    <other_name>PEG-L-Asparaginase (Enzon - Kyowa Hakko)</other_name>
    <other_name>PEGLA</other_name>
    <other_name>Polyethylene Glycol L-Asparaginase</other_name>
    <other_name>Polyethylene Glycol-L-Asparaginase</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm A (standard risk MLL-G)</arm_group_label>
    <arm_group_label>Arm B (IR/HR MLL-R chemotherapy)</arm_group_label>
    <arm_group_label>Arm C (IR/HR MLL-R chemotherapy and lestaurtinib)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm A (standard risk MLL-G)</arm_group_label>
    <arm_group_label>Arm B (IR/HR MLL-R chemotherapy)</arm_group_label>
    <arm_group_label>Arm C (IR/HR MLL-R chemotherapy and lestaurtinib)</arm_group_label>
    <other_name>.delta.1-Cortisone</other_name>
    <other_name>1, 2-Dehydrocortisone</other_name>
    <other_name>Adasone</other_name>
    <other_name>Cortancyl</other_name>
    <other_name>Dacortin</other_name>
    <other_name>DeCortin</other_name>
    <other_name>Decortisyl</other_name>
    <other_name>Decorton</other_name>
    <other_name>Delta 1-Cortisone</other_name>
    <other_name>Delta-Dome</other_name>
    <other_name>Deltacortene</other_name>
    <other_name>Deltacortisone</other_name>
    <other_name>Deltadehydrocortisone</other_name>
    <other_name>Deltasone</other_name>
    <other_name>Deltison</other_name>
    <other_name>Deltra</other_name>
    <other_name>Econosone</other_name>
    <other_name>Lisacort</other_name>
    <other_name>Meprosona-F</other_name>
    <other_name>Metacortandracin</other_name>
    <other_name>Meticorten</other_name>
    <other_name>Ofisolona</other_name>
    <other_name>Orasone</other_name>
    <other_name>Panafcort</other_name>
    <other_name>Panasol-S</other_name>
    <other_name>Paracort</other_name>
    <other_name>PRED</other_name>
    <other_name>Predicor</other_name>
    <other_name>Predicorten</other_name>
    <other_name>Prednicen-M</other_name>
    <other_name>Prednicort</other_name>
    <other_name>Prednidib</other_name>
    <other_name>Prednilonga</other_name>
    <other_name>Predniment</other_name>
    <other_name>Prednisonum</other_name>
    <other_name>Prednitone</other_name>
    <other_name>Promifen</other_name>
    <other_name>Servisone</other_name>
    <other_name>SK-Prednisone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Therapeutic Hydrocortisone</intervention_name>
    <description>Given IT</description>
    <arm_group_label>Arm A (standard risk MLL-G)</arm_group_label>
    <arm_group_label>Arm B (IR/HR MLL-R chemotherapy)</arm_group_label>
    <arm_group_label>Arm C (IR/HR MLL-R chemotherapy and lestaurtinib)</arm_group_label>
    <other_name>Aeroseb-HC</other_name>
    <other_name>Barseb HC</other_name>
    <other_name>Barseb-HC</other_name>
    <other_name>Cetacort</other_name>
    <other_name>Cort-Dome</other_name>
    <other_name>Cortef</other_name>
    <other_name>Cortenema</other_name>
    <other_name>Cortifan</other_name>
    <other_name>Cortisol</other_name>
    <other_name>Cortispray</other_name>
    <other_name>Cortril</other_name>
    <other_name>Dermacort</other_name>
    <other_name>Domolene</other_name>
    <other_name>Eldecort</other_name>
    <other_name>Hautosone</other_name>
    <other_name>Heb-Cort</other_name>
    <other_name>HYDROCORTISONE</other_name>
    <other_name>Hydrocortone</other_name>
    <other_name>Hytone</other_name>
    <other_name>Komed-HC</other_name>
    <other_name>Nutracort</other_name>
    <other_name>Proctocort</other_name>
    <other_name>Rectoid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine Sulfate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (standard risk MLL-G)</arm_group_label>
    <arm_group_label>Arm B (IR/HR MLL-R chemotherapy)</arm_group_label>
    <arm_group_label>Arm C (IR/HR MLL-R chemotherapy and lestaurtinib)</arm_group_label>
    <other_name>Kyocristine</other_name>
    <other_name>Leurocristine sulfate</other_name>
    <other_name>Leurocristine, sulfate</other_name>
    <other_name>Oncovin</other_name>
    <other_name>Vincasar</other_name>
    <other_name>Vincosid</other_name>
    <other_name>Vincrex</other_name>
    <other_name>Vincristine, sulfate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be enrolled on a Children's Oncology Group (COG) ALL Classification
             Study (AALL08B1) prior to enrollment on AALL0631

          -  Patients must be newly diagnosed with acute lymphoblastic leukemia (ALL) or acute
             undifferentiated leukemia (AUL); patients with T-cell ALL are eligible; patients with
             bilineage or biphenotypic acute leukemia are eligible, provided the morphology and
             immunophenotype are predominately lymphoid

          -  Patients with mature B-cell ALL or acute myelogenous leukemia (AML) are NOT eligible

          -  Patients with Down syndrome are NOT eligible

          -  Patients must be previously untreated with the exception of steroids and intrathecal
             chemotherapy; no other systemic chemotherapy may have been administered; patients
             receiving prior steroid therapy are eligible for study; any amount of steroid
             pretreatment will not affect initial induction assignment as long as the patient meets
             all other eligibility criteria; IT chemotherapy per protocol is allowed for patient
             convenience at the time of the diagnostic bone marrow or venous line placement to
             avoid second lumbar puncture; (note: the central nervous system [CNS] status must be
             determined based on a sample obtained prior to administration of any systemic or
             intrathecal chemotherapy, except for steroid pretreatment); systemic chemotherapy must
             begin within 72 hours of this IT therapy

          -  All patients and/or their parents or legal guardians must sign a written informed
             consent

          -  All institutional, Food and Drug Administration (FDA), and National Cancer Institute
             (NCI) requirements for human studies must be met
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Year</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joanne Hilden</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alabama at Birmingham Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phoenix Childrens Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202-3591</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Downey Medical Center</name>
      <address>
        <city>Downey</city>
        <state>California</state>
        <zip>90242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miller Children's and Women's Hospital Long Beach</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Central California</name>
      <address>
        <city>Madera</city>
        <state>California</state>
        <zip>93636-8762</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Research Center at Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609-1809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente-Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lucile Packard Children's Hospital Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Davis Comprehensive Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital - San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Medical Center-Parnassus</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Medical Center-Mission Bay</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connecticut Children's Medical Center</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alfred I duPont Hospital for Children</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedStar Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lee Memorial Health System</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Golisano Children's Hospital of Southwest Florida</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida Health Science Center - Gainesville</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic-Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine-Sylvester Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Cancer Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arnold Palmer Hospital for Children</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic - Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UF Cancer Center at Orlando Health</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32827</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic - Pensacola</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins All Children's Hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Joseph's Hospital/Children's Hospital-Tampa</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Mary's Hospital</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta - Egleston</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augusta University Medical Center</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Health University Medical Center</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Hawaii Cancer Center</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kapiolani Medical Center for Women and Children</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96826</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tripler Army Medical Center</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96859</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Mountain States Tumor Institute</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lurie Children's Hospital-Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advocate Children's Hospital-Oak Lawn</name>
      <address>
        <city>Oak Lawn</city>
        <state>Illinois</state>
        <zip>60453</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advocate Children's Hospital-Park Ridge</name>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <zip>60068</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advocate Lutheran General Hospital</name>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <zip>60068</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Vincent Hospital and Health Care Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blank Children's Hospital</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky/Markey Cancer Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norton Children's Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane University Health Sciences Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital New Orleans</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Maine Medical Center</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland/Greenebaum Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sinai Hospital of Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University/Sidney Kimmel Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Floating Hospital for Children at Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C S Mott Children's Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University/Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan State University Clinical Center</name>
      <address>
        <city>East Lansing</city>
        <state>Michigan</state>
        <zip>48824-7016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hurley Medical Center</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helen DeVos Children's Hospital at Spectrum Health</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bronson Methodist Hospital</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kalamazoo Center for Medical Studies</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospitals and Clinics of Minnesota - Minneapolis</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota/Masonic Cancer Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia Regional</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Childrens Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital Saint Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Medical Center of Omaha</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nevada Cancer Research Foundation CCOP</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Specialty Center of Nevada II</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summerlin Hospital Medical Center</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Barnabas Medical Center</name>
      <address>
        <city>Livingston</city>
        <state>New Jersey</state>
        <zip>07039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morristown Medical Center</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Peter's University Hospital</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newark Beth Israel Medical Center</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Joseph's Regional Medical Center</name>
      <address>
        <city>Paterson</city>
        <state>New Jersey</state>
        <zip>07503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Overlook Hospital</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <zip>07902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Cancer Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center - Moses Campus</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Winthrop Hospital</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Steven and Alexandra Cohen Children's Medical Center of New York</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laura and Isaac Perlmutter Cancer Center at NYU Langone</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State University of New York Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mission Hospital Inc-Memorial Campus</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNC Lineberger Comprehensive Cancer Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center/Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novant Health Presbyterian Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Carolina University</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanford Broadway Medical Center</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Medical Center of Akron</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rainbow Babies and Childrens Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dayton Children's Hospital</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Toledo Hospital/Toledo Children's Hospital</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Children's Hospital</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Legacy Emanuel Children's Hospital</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Legacy Emanuel Hospital and Health Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geisinger Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Children's Hospital</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Christopher's Hospital for Children</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palmetto Health Richland</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BI-LO Charities Children's Cancer Center</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenville Cancer Treatment Center</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanford USD Medical Center - Sioux Falls</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57117-5134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Tennessee Childrens Hospital</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37916</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University/Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Tech University Health Sciences Center-Amarillo</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dell Children's Medical Center of Central Texas</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Driscoll Children's Hospital</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78411</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical City Dallas Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern/Simmons Cancer Center-Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cook Children's Medical Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Covenant Children's Hospital</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Children's Hospital of South Texas</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott and White Memorial Hospital</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Children's Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Vermont College of Medicine</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inova Fairfax Hospital</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of The King's Daughters</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Sacred Heart Medical Center and Children's Hospital</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Bridge Children's Hospital and Health Center</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Madigan Army Medical Center</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Virginia University Charleston Division</name>
      <address>
        <city>Charleston</city>
        <state>West Virginia</state>
        <zip>25304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Vincent Hospital Cancer Center Green Bay</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marshfield Clinic</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital for Children</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6008</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alberta Children's Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3B 6A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>British Columbia Children's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Janeway Child Health Centre</name>
      <address>
        <city>Saint John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IWK Health Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3K 6R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Eastern Ontario</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Montreal Children's Hospital of the MUHC</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3H 1P3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saskatoon Cancer Centre</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Starship Children's Hospital</name>
      <address>
        <city>Grafton</city>
        <state>Auckland</state>
        <zip>1145</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Israel</country>
  </removed_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>November 9, 2007</study_first_submitted>
  <study_first_submitted_qc>November 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 12, 2007</study_first_posted>
  <results_first_submitted>September 26, 2018</results_first_submitted>
  <results_first_submitted_qc>November 13, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 10, 2018</results_first_posted>
  <last_update_submitted>March 12, 2020</last_update_submitted>
  <last_update_submitted_qc>March 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Hydrocortisone hemisuccinate</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Cortisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>Mercaptopurine</mesh_term>
    <mesh_term>Podophyllotoxin</mesh_term>
    <mesh_term>Pegaspargase</mesh_term>
    <mesh_term>Ichthammol</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 5, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/93/NCT00557193/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Infants with Acute Lymphoblastic Leukemia (ALL)</recruitment_details>
      <pre_assignment_details>MLL-germline [G] to SR (Arm A/Group 1), MLL-rearranged [R] randomized/assigned to Arm B (Group2; chemo) or Arm C (Group3; chemo+lestaurtinib) with dose determined by age at dx (&gt;=90 days is IR and &lt;90 days is HR)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Induction (All Patients)</title>
          <description>All Patients for Induction (not assigned).</description>
        </group>
        <group group_id="P2">
          <title>Arm A (Standard Risk MLL-G)</title>
          <description>Eligible patients with MLL-G (germline, or non-rearranged)
Asparaginase: Given IV, IM, or PO
Cyclophosphamide: Given IV
Cytarabine: Given IV or IT
Daunorubicin Hydrochloride: Given IV
Dexamethasone: Given IV or PO
Etoposide: Given IV
Filgrastim: Given IV or SC
Laboratory Biomarker Analysis: Correlative studies
Leucovorin Calcium: Given IV
Mercaptopurine: Given PO
Methotrexate: Given IV, IT, or PO
Methylprednisolone: Given IV
Pegaspargase: Given IM
Pharmacological Study: Correlative studies
Prednisone: Given PO
Therapeutic Hydrocortisone: Given IT
Vincristine Sulfate: Given IV</description>
        </group>
        <group group_id="P3">
          <title>Arm B (IR/HR MLL-R Chemotherapy)</title>
          <description>Eligible patients with MLL-R (rearranged). Considered Intermediate Risk (IR) if age &gt;= 90 days at diagnosis and High Risk (HR) if age &lt; 90 days at diagnosis.
Asparaginase: Given IV, IM, or PO
Cyclophosphamide: Given IV
Cytarabine: Given IV or IT
Daunorubicin Hydrochloride: Given IV
Dexamethasone: Given IV or PO
Etoposide: Given IV
Filgrastim: Given IV or SC
Laboratory Biomarker Analysis: Correlative studies
Leucovorin Calcium: Given IV
Mercaptopurine: Given PO
Methotrexate: Given IV, IT, or PO
Methylprednisolone: Given IV
Pegaspargase: Given IM
Pharmacological Study: Correlative studies
Prednisone: Given PO
Therapeutic Hydrocortisone: Given IT
Vincristine Sulfate: Given IV</description>
        </group>
        <group group_id="P4">
          <title>Arm C (Safety/ Dose Level 1)</title>
          <description>Arm C, IR/HR MLL-R chemotherapy and lestaurtinib at Dose Level 1 (DL1) (HR: 3.5 mg/kg/day; SR: 4 mg/kg/day)</description>
        </group>
        <group group_id="P5">
          <title>ARM C (Safety/ Dose Level 2)</title>
          <description>Arm C, IR/HR MLL-R chemotherapy and lestaurtinib at Dose Level 2 (DL2) (HR: 4.25 mg/kg/day; SR: 5 mg/kg/day)</description>
        </group>
        <group group_id="P6">
          <title>Arm C (Efficacy/ Dose Level 2)</title>
          <description>Arm C, IR/HR MLL-R chemotherapy and lestaurtinib at Dose Level 2 (DL2)-Efficacy (HR: 4.25 mg/kg/day; SR: 5 mg/kg/day)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Induction</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="218"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="192"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refusal of Further Protocol Therapy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligible</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inevaluable for post Induction</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to receive Lestaurtinib-Not in US</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Post Induction Therapy by Tx Assignment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="60"/>
                <participants group_id="P3" count="54"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="22"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="32"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="37"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refusal of Further Protocol</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Relapse</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Developed second malignant neoplasm</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient Moved to Another Institution</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Induction Failure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Patients</title>
          <description>All patients for Induction</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="218"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="218"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.54" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="160"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="167"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New Zealand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Probability for Event-free Survival (EFS) for Patients on Arm C at Dose Level 2 (DL2)</title>
        <description>EFS time is defined as time from randomization to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. EFS is constructed using the Kaplan-Meier life table method with confidence interval based on standard errors computed using the method of Peto and Peto.</description>
        <time_frame>From start of post-induction therapy for up to 10 years</time_frame>
        <population>All 67 patients on Arm C (Safety and Efficacy at Dose Level 2) were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm C (Safety/Efficacy Dose Level 2)</title>
            <description>Arm C (Safety and Efficacy), IR/HR MLL-R chemotherapy and lestaurtinib at DL2 (HR: 4.25 mg/kg/day; SR: 5 mg/kg/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Probability for Event-free Survival (EFS) for Patients on Arm C at Dose Level 2 (DL2)</title>
          <description>EFS time is defined as time from randomization to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. EFS is constructed using the Kaplan-Meier life table method with confidence interval based on standard errors computed using the method of Peto and Peto.</description>
          <population>All 67 patients on Arm C (Safety and Efficacy at Dose Level 2) were included in the analysis.</population>
          <units>percentage probability</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.82" lower_limit="25.98" upper_limit="45.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Probability for Event-free Survival (EFS) of MLL-R Infants Treated With Combination Chemotherapy With or Without Lestaurtinib at DL2</title>
        <description>Event Free Probability where EFS time is defined as time from randomization to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. EFS is constructed using the Kaplan-Meier life table method with confidence interval based on standard errors computed using the method of Peto and Peto. EFS will be compared between patients on treatment Arm C at DL2 to those on Arm B.</description>
        <time_frame>From start of post-induction therapy for up to 10 years.</time_frame>
        <population>All eligible Arm B and ARM C (Dose Level 2) patients were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm B (IR/HR MLL-R Chemotherapy)</title>
            <description>Eligible patients with MLL-R (rearranged). Considered Intermediate Risk (IR) if age &gt;= 90 days at diagnosis and High Risk (HR) if age &lt; 90 days at diagnosis.
Asparaginase: Given IV, IM, or PO
Cyclophosphamide: Given IV
Cytarabine: Given IV or IT
Daunorubicin Hydrochloride: Given IV
Dexamethasone: Given IV or PO
Etoposide: Given IV
Filgrastim: Given IV or SC
Laboratory Biomarker Analysis: Correlative studies
Leucovorin Calcium: Given IV
Mercaptopurine: Given PO
Methotrexate: Given IV, IT, or PO
Methylprednisolone: Given IV
Pegaspargase: Given IM
Pharmacological Study: Correlative studies
Prednisone: Given PO
Therapeutic Hydrocortisone: Given IT
Vincristine Sulfate: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Arm C (IR/HR MLL-R Chemotherapy and Lestaurtinib)</title>
            <description>Eligible patients with MLL-R (rearranged). Considered Intermediate Risk (IR) if age &gt;= 90 days at diagnosis and High Risk (HR) if age &lt; 90 days at diagnosis.
Asparaginase: Given IV, IM, or PO
Cyclophosphamide: Given IV
Cytarabine: Given IV or IT
Daunorubicin Hydrochloride: Given IV
Dexamethasone: Given IV or PO
Etoposide: Given IV
Filgrastim: Given IV or SC
Laboratory Biomarker Analysis: Correlative studies
Lestaurtinib: Given PO
Leucovorin Calcium: Given IV
Mercaptopurine: Given PO
Methotrexate: Given IV, IT, or PO
Methylprednisolone: Given IV
Pegaspargase: Given IM
Pharmacological Study: Correlative studies
Prednisone: Given PO
Therapeutic Hydrocortisone: Given IT
Vincristine Sulfate: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Probability for Event-free Survival (EFS) of MLL-R Infants Treated With Combination Chemotherapy With or Without Lestaurtinib at DL2</title>
          <description>Event Free Probability where EFS time is defined as time from randomization to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. EFS is constructed using the Kaplan-Meier life table method with confidence interval based on standard errors computed using the method of Peto and Peto. EFS will be compared between patients on treatment Arm C at DL2 to those on Arm B.</description>
          <population>All eligible Arm B and ARM C (Dose Level 2) patients were included in the analysis.</population>
          <units>percent probability</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.89" lower_limit="27.98" upper_limit="49.80"/>
                    <measurement group_id="O2" value="35.82" lower_limit="25.98" upper_limit="45.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A one-sided log rank test will be used for testing whether the EFS in Arm C (chemo+lest) at DL2 is greater than the EFS in Arm B (chemo). This is equivalent to testing the null hypothesis of hazard ratio (HR)=1 versus the alternative of HR&lt;1.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.672</p_value>
            <p_value_desc>A priori significance level threshold of alpha=0.15</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.107</param_value>
            <ci_percent>85</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>1.403</ci_upper_limit>
            <estimate_desc>Arm C is the numerator and Arm B is the denominator of the estimated hazard ratio</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Experienced Lestaurtinib-related Dose Limiting Toxicity (DLT)</title>
        <description>Lestaurtinib-related dose-limiting toxicity proportions, as measured by NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, will by summarized by dose level for Safety phase patients.</description>
        <time_frame>Up to 12 weeks from start of induction</time_frame>
        <population>Arm C patients of Safety Phase who were evaluable for DLT. The first 10 evaluable patients enrolled on each dose level were included for monitoring dose limiting toxicity.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm C (IR/HR MLL-R Chemotherapy and Lestaurtinib-Dose Level 1)</title>
            <description>Evaluable Arm C, IR/HR MLL-R chemotherapy and lestaurtinib at DL1 (HR: 3.5 mg/kg/day; SR: 4 mg/kg/day)</description>
          </group>
          <group group_id="O2">
            <title>Arm C (IR/HR MLL-R Chemotherapy and Lestaurtinib-Dose Level 2)</title>
            <description>Evaluable Arm C, IR/HR MLL-R chemotherapy and lestaurtinib at DL2 (HR: 4.25 mg/kg/day; SR: 5 mg/kg/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Experienced Lestaurtinib-related Dose Limiting Toxicity (DLT)</title>
          <description>Lestaurtinib-related dose-limiting toxicity proportions, as measured by NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, will by summarized by dose level for Safety phase patients.</description>
          <population>Arm C patients of Safety Phase who were evaluable for DLT. The first 10 evaluable patients enrolled on each dose level were included for monitoring dose limiting toxicity.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic AGP Levels in Infants Given Lestaurtinib at DL2 in Combination With Chemotherapy</title>
        <description>Pharmacokinetic AGP levels in infants given lestaurtinib at DL2 in combination with chemotherapy will be described with mean and standard deviation for those with available data.</description>
        <time_frame>Up to 12 weeks</time_frame>
        <population>Data was and never will be collected</population>
        <group_list>
          <group group_id="O1">
            <title>Arm C (IR/HR MLL-R Chemotherapy and Lestaurtinib)</title>
            <description>Population Description: Eligible patients with MLL-R (rearranged). Considered Intermediate Risk (IR) if age &gt;= 90 days at diagnosis and High Risk (HR) if age &lt; 90 days at diagnosis.
Asparaginase: Given IV, IM, or PO
Cyclophosphamide: Given IV
Cytarabine: Given IV or IT
Daunorubicin Hydrochloride: Given IV
Dexamethasone: Given IV or PO
Etoposide: Given IV
Filgrastim: Given IV or SC
Laboratory Biomarker Analysis: Correlative studies
Lestaurtinib: Given PO
Leucovorin Calcium: Given IV
Mercaptopurine: Given PO
Methotrexate: Given IV, IT, or PO
Methylprednisolone: Given IV
Pegaspargase: Given IM
Pharmacological Study: Correlative studies
Prednisone: Given PO
Therapeutic Hydrocortisone: Given IT
Vincristine Sulfate: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic AGP Levels in Infants Given Lestaurtinib at DL2 in Combination With Chemotherapy</title>
          <description>Pharmacokinetic AGP levels in infants given lestaurtinib at DL2 in combination with chemotherapy will be described with mean and standard deviation for those with available data.</description>
          <population>Data was and never will be collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Albumin in Infants Given Lestaurtinib at DL2 in Combination With Chemotherapy</title>
        <description>Pharmacokinetic albumin in infants given lestaurtinib at DL2 in combination with chemotherapy will be described with mean and standard deviation for those with available data.</description>
        <time_frame>Up to 12 weeks</time_frame>
        <population>Data was and never will be collected</population>
        <group_list>
          <group group_id="O1">
            <title>Arm C (IR/HR MLL-R Chemotherapy and Lestaurtinib)</title>
            <description>Population Description: Eligible patients with MLL-R (rearranged). Considered Intermediate Risk (IR) if age &gt;= 90 days at diagnosis and High Risk (HR) if age &lt; 90 days at diagnosis.
Asparaginase: Given IV, IM, or PO
Cyclophosphamide: Given IV
Cytarabine: Given IV or IT
Daunorubicin Hydrochloride: Given IV
Dexamethasone: Given IV or PO
Etoposide: Given IV
Filgrastim: Given IV or SC
Laboratory Biomarker Analysis: Correlative studies
Lestaurtinib: Given PO
Leucovorin Calcium: Given IV
Mercaptopurine: Given PO
Methotrexate: Given IV, IT, or PO
Methylprednisolone: Given IV
Pegaspargase: Given IM
Pharmacological Study: Correlative studies
Prednisone: Given PO
Therapeutic Hydrocortisone: Given IT
Vincristine Sulfate: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Albumin in Infants Given Lestaurtinib at DL2 in Combination With Chemotherapy</title>
          <description>Pharmacokinetic albumin in infants given lestaurtinib at DL2 in combination with chemotherapy will be described with mean and standard deviation for those with available data.</description>
          <population>Data was and never will be collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamics PIA Levels in Infants Given Lestaurtinib at DL2 in Combination With Chemotherapy</title>
        <description>Summarized with mean and standard deviation for those with available data in Arm C</description>
        <time_frame>Sampled between weeks 6-12 from start of induction</time_frame>
        <population>Arm C Dose Level 2 (DL2) patients who had data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm C (Safety/Efficacy Dose Level 2)</title>
            <description>Arm C (Safety and Efficacy), IR/HR MLL-R chemotherapy and lestaurtinib at DL2 (HR: 4.25 mg/kg/day; SR: 5 mg/kg/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamics PIA Levels in Infants Given Lestaurtinib at DL2 in Combination With Chemotherapy</title>
          <description>Summarized with mean and standard deviation for those with available data in Arm C</description>
          <population>Arm C Dose Level 2 (DL2) patients who had data available for analysis.</population>
          <units>Activity percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.00" spread="22.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Describe FLT3 Protein Expression as a Molecular Mechanism of Primary Resistance to Lestaurtinib in Leukemic Blasts</title>
        <description>Described via mean and standard deviation by group.</description>
        <time_frame>Sampled at the start of induction</time_frame>
        <population>Patients who had data collected</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Standard Risk MLL-G)</title>
            <description>Population Description: Eligible patients with MLL-G (germline, or non-rearranged)
Asparaginase: Given IV, IM, or PO
Cyclophosphamide: Given IV
Cytarabine: Given IV or IT
Daunorubicin Hydrochloride: Given IV
Dexamethasone: Given IV or PO
Etoposide: Given IV
Filgrastim: Given IV or SC
Laboratory Biomarker Analysis: Correlative studies
Leucovorin Calcium: Given IV
Mercaptopurine: Given PO
Methotrexate: Given IV, IT, or PO
Methylprednisolone: Given IV
Pegaspargase: Given IM
Pharmacological Study: Correlative studies
Prednisone: Given PO
Therapeutic Hydrocortisone: Given IT
Vincristine Sulfate: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Arm B (IR/HR MLL-R Chemotherapy)</title>
            <description>Population Description: Eligible patients with MLL-R (rearranged). Considered Intermediate Risk (IR) if age &gt;= 90 days at diagnosis and High Risk (HR) if age &lt; 90 days at diagnosis.
Asparaginase: Given IV, IM, or PO
Cyclophosphamide: Given IV
Cytarabine: Given IV or IT
Daunorubicin Hydrochloride: Given IV
Dexamethasone: Given IV or PO
Etoposide: Given IV
Filgrastim: Given IV or SC
Laboratory Biomarker Analysis: Correlative studies
Leucovorin Calcium: Given IV
Mercaptopurine: Given PO
Methotrexate: Given IV, IT, or PO
Methylprednisolone: Given IV
Pegaspargase: Given IM
Pharmacological Study: Correlative studies
Prednisone: Given PO
Therapeutic Hydrocortisone: Given IT
Vincristine Sulfate: Given IV</description>
          </group>
          <group group_id="O3">
            <title>Arm C (IR/HR MLL-R Chemotherapy and Lestaurtinib)</title>
            <description>Population Description: Eligible patients with MLL-R (rearranged). Considered Intermediate Risk (IR) if age &gt;= 90 days at diagnosis and High Risk (HR) if age &lt; 90 days at diagnosis.
Asparaginase: Given IV, IM, or PO
Cyclophosphamide: Given IV
Cytarabine: Given IV or IT
Daunorubicin Hydrochloride: Given IV
Dexamethasone: Given IV or PO
Etoposide: Given IV
Filgrastim: Given IV or SC
Laboratory Biomarker Analysis: Correlative studies
Lestaurtinib: Given PO
Leucovorin Calcium: Given IV
Mercaptopurine: Given PO
Methotrexate: Given IV, IT, or PO
Methylprednisolone: Given IV
Pegaspargase: Given IM
Pharmacological Study: Correlative studies
Prednisone: Given PO
Therapeutic Hydrocortisone: Given IT
Vincristine Sulfate: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Describe FLT3 Protein Expression as a Molecular Mechanism of Primary Resistance to Lestaurtinib in Leukemic Blasts</title>
          <description>Described via mean and standard deviation by group.</description>
          <population>Patients who had data collected</population>
          <units>qPCR fold expression ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" spread="2.12"/>
                    <measurement group_id="O2" value="7.85" spread="10.65"/>
                    <measurement group_id="O3" value="5.83" spread="5.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Describe FLT3 Protein Expression as a Molecular Mechanism of Acquired Resistance to Lestaurtinib in Leukemic Blasts</title>
        <description>Described via means and standard deviations in available Arm C relapse samples</description>
        <time_frame>At relapse (up to 3 years)</time_frame>
        <population>Arm C Dose Level 2 patients who relapsed and had data collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm C (Safety/Efficacy Dose Level 2)</title>
            <description>Arm C (Safety and Efficacy), IR/HR MLL-R chemotherapy and lestaurtinib at DL2 (HR: 4.25 mg/kg/day; SR: 5 mg/kg/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Describe FLT3 Protein Expression as a Molecular Mechanism of Acquired Resistance to Lestaurtinib in Leukemic Blasts</title>
          <description>Described via means and standard deviations in available Arm C relapse samples</description>
          <population>Arm C Dose Level 2 patients who relapsed and had data collected.</population>
          <units>qPCR fold expression ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.73" spread="4.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Describe in Vitro Sensitivity as a Molecular Mechanism of Primary Resistance to Lestaurtinib in Leukemic Blasts</title>
        <description>Described via means and standard deviations in samples which have primary resistance to lestaurtinib</description>
        <time_frame>Sampled at the start of induction</time_frame>
        <population>Patients who had data collected</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Standard Risk MLL-G)</title>
            <description>Population Description: Eligible patients with MLL-G (germline, or non-rearranged)
Asparaginase: Given IV, IM, or PO
Cyclophosphamide: Given IV
Cytarabine: Given IV or IT
Daunorubicin Hydrochloride: Given IV
Dexamethasone: Given IV or PO
Etoposide: Given IV
Filgrastim: Given IV or SC
Laboratory Biomarker Analysis: Correlative studies
Leucovorin Calcium: Given IV
Mercaptopurine: Given PO
Methotrexate: Given IV, IT, or PO
Methylprednisolone: Given IV
Pegaspargase: Given IM
Pharmacological Study: Correlative studies
Prednisone: Given PO
Therapeutic Hydrocortisone: Given IT
Vincristine Sulfate: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Arm B (IR/HR MLL-R Chemotherapy)</title>
            <description>Population Description: Eligible patients with MLL-R (rearranged). Considered Intermediate Risk (IR) if age &gt;= 90 days at diagnosis and High Risk (HR) if age &lt; 90 days at diagnosis.
Asparaginase: Given IV, IM, or PO
Cyclophosphamide: Given IV
Cytarabine: Given IV or IT
Daunorubicin Hydrochloride: Given IV
Dexamethasone: Given IV or PO
Etoposide: Given IV
Filgrastim: Given IV or SC
Laboratory Biomarker Analysis: Correlative studies
Leucovorin Calcium: Given IV
Mercaptopurine: Given PO
Methotrexate: Given IV, IT, or PO
Methylprednisolone: Given IV
Pegaspargase: Given IM
Pharmacological Study: Correlative studies
Prednisone: Given PO
Therapeutic Hydrocortisone: Given IT
Vincristine Sulfate: Given IV</description>
          </group>
          <group group_id="O3">
            <title>Arm C (IR/HR MLL-R Chemotherapy and Lestaurtinib)</title>
            <description>Population Description: Eligible patients with MLL-R (rearranged). Considered Intermediate Risk (IR) if age &gt;= 90 days at diagnosis and High Risk (HR) if age &lt; 90 days at diagnosis.
Asparaginase: Given IV, IM, or PO
Cyclophosphamide: Given IV
Cytarabine: Given IV or IT
Daunorubicin Hydrochloride: Given IV
Dexamethasone: Given IV or PO
Etoposide: Given IV
Filgrastim: Given IV or SC
Laboratory Biomarker Analysis: Correlative studies
Lestaurtinib: Given PO
Leucovorin Calcium: Given IV
Mercaptopurine: Given PO
Methotrexate: Given IV, IT, or PO
Methylprednisolone: Given IV
Pegaspargase: Given IM
Pharmacological Study: Correlative studies
Prednisone: Given PO
Therapeutic Hydrocortisone: Given IT
Vincristine Sulfate: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Describe in Vitro Sensitivity as a Molecular Mechanism of Primary Resistance to Lestaurtinib in Leukemic Blasts</title>
          <description>Described via means and standard deviations in samples which have primary resistance to lestaurtinib</description>
          <population>Patients who had data collected</population>
          <units>Proportion of cells that are viable</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" spread="0.14"/>
                    <measurement group_id="O2" value="0.48" spread="0.19"/>
                    <measurement group_id="O3" value="0.47" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Describe in Vitro Sensitivity as a Molecular Mechanism of Acquired Resistance to Lestaurtinib in Leukemic Blasts</title>
        <description>Described via means and standard deviations in samples which have acquired resistance to lestaurtinib</description>
        <time_frame>At relapse (up to 3 years)</time_frame>
        <population>Arm C Dose Level 2 patients who relapsed and had data collected</population>
        <group_list>
          <group group_id="O1">
            <title>Arm C (IR/HR MLL-R Chemotherapy and Lestaurtinib)</title>
            <description>Population Description: Eligible patients with MLL-R (rearranged). Considered Intermediate Risk (IR) if age &gt;= 90 days at diagnosis and High Risk (HR) if age &lt; 90 days at diagnosis.
Asparaginase: Given IV, IM, or PO
Cyclophosphamide: Given IV
Cytarabine: Given IV or IT
Daunorubicin Hydrochloride: Given IV
Dexamethasone: Given IV or PO
Etoposide: Given IV
Filgrastim: Given IV or SC
Laboratory Biomarker Analysis: Correlative studies
Lestaurtinib: Given PO
Leucovorin Calcium: Given IV
Mercaptopurine: Given PO
Methotrexate: Given IV, IT, or PO
Methylprednisolone: Given IV
Pegaspargase: Given IM
Pharmacological Study: Correlative studies
Prednisone: Given PO
Therapeutic Hydrocortisone: Given IT
Vincristine Sulfate: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Describe in Vitro Sensitivity as a Molecular Mechanism of Acquired Resistance to Lestaurtinib in Leukemic Blasts</title>
          <description>Described via means and standard deviations in samples which have acquired resistance to lestaurtinib</description>
          <population>Arm C Dose Level 2 patients who relapsed and had data collected</population>
          <units>Proportion of cells that are viable</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.69" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Probability of Event Free Survival (EFS) by MRD Status and Treatment Arm</title>
        <description>Three-year EFS estimates and 90% CI will be reported by treatment arm and end-induction MRD status.</description>
        <time_frame>3 Years from end of Induction)</time_frame>
        <population>Patients who had data collected</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (MRD Negative)</title>
            <description>Arm A, standard risk MLL-G</description>
          </group>
          <group group_id="O2">
            <title>Arm A (MRD Positive)</title>
            <description>Arm A, standard risk MLL-G</description>
          </group>
          <group group_id="O3">
            <title>Arm B (MRD Negative)</title>
            <description>Arm B, IR/HR MLL-R chemotherapy</description>
          </group>
          <group group_id="O4">
            <title>Arm B (MRD Positive)</title>
            <description>Arm B, IR/HR MLL-R chemotherapy</description>
          </group>
          <group group_id="O5">
            <title>Arm C (MRD Negative)</title>
            <description>Arm C, IR/HR MLL-R chemotherapy and lestaurtinib</description>
          </group>
          <group group_id="O6">
            <title>Arm C (MRD Positive)</title>
            <description>Arm C, IR/HR MLL-R chemotherapy and lestaurtinib</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Probability of Event Free Survival (EFS) by MRD Status and Treatment Arm</title>
          <description>Three-year EFS estimates and 90% CI will be reported by treatment arm and end-induction MRD status.</description>
          <population>Patients who had data collected</population>
          <units>percent probability</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="27"/>
                <count group_id="O6" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.05" lower_limit="77.36" upper_limit="94.74"/>
                    <measurement group_id="O2" value="87.5" lower_limit="68.27" upper_limit="100"/>
                    <measurement group_id="O3" value="47.37" lower_limit="28.53" upper_limit="66.21"/>
                    <measurement group_id="O4" value="22.73" lower_limit="8.04" upper_limit="37.42"/>
                    <measurement group_id="O5" value="51.85" lower_limit="36.03" upper_limit="67.67"/>
                    <measurement group_id="O6" value="27.03" lower_limit="13.61" upper_limit="40.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Identification of Gene Expression Patterns in Diagnostic Infant Leukemia Samples That Correlate With Survival Outcomes</title>
        <description>EFS outcomes will be reported by genotype.</description>
        <time_frame>At 3 years</time_frame>
        <population>Data was and never will never be collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Standard Risk MLL-G)</title>
            <description>Population Description: Eligible patients with MLL-G (germline, or non-rearranged)
Asparaginase: Given IV, IM, or PO
Cyclophosphamide: Given IV
Cytarabine: Given IV or IT
Daunorubicin Hydrochloride: Given IV
Dexamethasone: Given IV or PO
Etoposide: Given IV
Filgrastim: Given IV or SC
Laboratory Biomarker Analysis: Correlative studies
Leucovorin Calcium: Given IV
Mercaptopurine: Given PO
Methotrexate: Given IV, IT, or PO
Methylprednisolone: Given IV
Pegaspargase: Given IM
Pharmacological Study: Correlative studies
Prednisone: Given PO
Therapeutic Hydrocortisone: Given IT
Vincristine Sulfate: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Arm B (IR/HR MLL-R Chemotherapy)</title>
            <description>Population Description: Eligible patients with MLL-R (rearranged). Considered Intermediate Risk (IR) if age &gt;= 90 days at diagnosis and High Risk (HR) if age &lt; 90 days at diagnosis.
Asparaginase: Given IV, IM, or PO
Cyclophosphamide: Given IV
Cytarabine: Given IV or IT
Daunorubicin Hydrochloride: Given IV
Dexamethasone: Given IV or PO
Etoposide: Given IV
Filgrastim: Given IV or SC
Laboratory Biomarker Analysis: Correlative studies
Leucovorin Calcium: Given IV
Mercaptopurine: Given PO
Methotrexate: Given IV, IT, or PO
Methylprednisolone: Given IV
Pegaspargase: Given IM
Pharmacological Study: Correlative studies
Prednisone: Given PO
Therapeutic Hydrocortisone: Given IT
Vincristine Sulfate: Given IV</description>
          </group>
          <group group_id="O3">
            <title>Arm C (IR/HR MLL-R Chemotherapy and Lestaurtinib)</title>
            <description>Population Description: Eligible patients with MLL-R (rearranged). Considered Intermediate Risk (IR) if age &gt;= 90 days at diagnosis and High Risk (HR) if age &lt; 90 days at diagnosis.
Asparaginase: Given IV, IM, or PO
Cyclophosphamide: Given IV
Cytarabine: Given IV or IT
Daunorubicin Hydrochloride: Given IV
Dexamethasone: Given IV or PO
Etoposide: Given IV
Filgrastim: Given IV or SC
Laboratory Biomarker Analysis: Correlative studies
Lestaurtinib: Given PO
Leucovorin Calcium: Given IV
Mercaptopurine: Given PO
Methotrexate: Given IV, IT, or PO
Methylprednisolone: Given IV
Pegaspargase: Given IM
Pharmacological Study: Correlative studies
Prednisone: Given PO
Therapeutic Hydrocortisone: Given IT
Vincristine Sulfate: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Identification of Gene Expression Patterns in Diagnostic Infant Leukemia Samples That Correlate With Survival Outcomes</title>
          <description>EFS outcomes will be reported by genotype.</description>
          <population>Data was and never will never be collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Identification of Gene Expression Patterns in Diagnostic Infant Leukemia Samples That Correlate With PIA Values</title>
        <description>Means and standard deviations of Plasma Inhibitory Activity (PIA) will be given by genotype</description>
        <time_frame>At 3 years</time_frame>
        <population>Data was and never will be collected</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Standard Risk MLL-G)</title>
            <description>Population Description: Eligible patients with MLL-G (germline, or non-rearranged)
Asparaginase: Given IV, IM, or PO
Cyclophosphamide: Given IV
Cytarabine: Given IV or IT
Daunorubicin Hydrochloride: Given IV
Dexamethasone: Given IV or PO
Etoposide: Given IV
Filgrastim: Given IV or SC
Laboratory Biomarker Analysis: Correlative studies
Leucovorin Calcium: Given IV
Mercaptopurine: Given PO
Methotrexate: Given IV, IT, or PO
Methylprednisolone: Given IV
Pegaspargase: Given IM
Pharmacological Study: Correlative studies
Prednisone: Given PO
Therapeutic Hydrocortisone: Given IT
Vincristine Sulfate: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Arm B (IR/HR MLL-R Chemotherapy)</title>
            <description>Population Description: Eligible patients with MLL-R (rearranged). Considered Intermediate Risk (IR) if age &gt;= 90 days at diagnosis and High Risk (HR) if age &lt; 90 days at diagnosis.
Asparaginase: Given IV, IM, or PO
Cyclophosphamide: Given IV
Cytarabine: Given IV or IT
Daunorubicin Hydrochloride: Given IV
Dexamethasone: Given IV or PO
Etoposide: Given IV
Filgrastim: Given IV or SC
Laboratory Biomarker Analysis: Correlative studies
Leucovorin Calcium: Given IV
Mercaptopurine: Given PO
Methotrexate: Given IV, IT, or PO
Methylprednisolone: Given IV
Pegaspargase: Given IM
Pharmacological Study: Correlative studies
Prednisone: Given PO
Therapeutic Hydrocortisone: Given IT
Vincristine Sulfate: Given IV</description>
          </group>
          <group group_id="O3">
            <title>Arm C (IR/HR MLL-R Chemotherapy and Lestaurtinib)</title>
            <description>Population Description: Eligible patients with MLL-R (rearranged). Considered Intermediate Risk (IR) if age &gt;= 90 days at diagnosis and High Risk (HR) if age &lt; 90 days at diagnosis.
Asparaginase: Given IV, IM, or PO
Cyclophosphamide: Given IV
Cytarabine: Given IV or IT
Daunorubicin Hydrochloride: Given IV
Dexamethasone: Given IV or PO
Etoposide: Given IV
Filgrastim: Given IV or SC
Laboratory Biomarker Analysis: Correlative studies
Lestaurtinib: Given PO
Leucovorin Calcium: Given IV
Mercaptopurine: Given PO
Methotrexate: Given IV, IT, or PO
Methylprednisolone: Given IV
Pegaspargase: Given IM
Pharmacological Study: Correlative studies
Prednisone: Given PO
Therapeutic Hydrocortisone: Given IT
Vincristine Sulfate: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Identification of Gene Expression Patterns in Diagnostic Infant Leukemia Samples That Correlate With PIA Values</title>
          <description>Means and standard deviations of Plasma Inhibitory Activity (PIA) will be given by genotype</description>
          <population>Data was and never will be collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Probability for Event-free Survival (EFS) for Patients on Arm A</title>
        <description>EFS time is defined as time from treatment assignment to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. EFS is constructed using the Kaplan-Meier life table method with confidence interval based on standard errors computed using the method of Peto and Peto.</description>
        <time_frame>From start of post-induction therapy for up to 10 years</time_frame>
        <population>All Eligible patients treated in Arm A (standard risk MLL-G).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Standard Risk MLL-G)</title>
            <description>Eligible patients with MLL-G (germline, or non-rearranged)
Asparaginase: Given IV, IM, or PO
Cyclophosphamide: Given IV
Cytarabine: Given IV or IT
Daunorubicin Hydrochloride: Given IV
Dexamethasone: Given IV or PO
Etoposide: Given IV
Filgrastim: Given IV or SC
Laboratory Biomarker Analysis: Correlative studies
Leucovorin Calcium: Given IV
Mercaptopurine: Given PO
Methotrexate: Given IV, IT, or PO
Methylprednisolone: Given IV
Pegaspargase: Given IM
Pharmacological Study: Correlative studies
Prednisone: Given PO
Therapeutic Hydrocortisone: Given IT
Vincristine Sulfate: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Probability for Event-free Survival (EFS) for Patients on Arm A</title>
          <description>EFS time is defined as time from treatment assignment to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. EFS is constructed using the Kaplan-Meier life table method with confidence interval based on standard errors computed using the method of Peto and Peto.</description>
          <population>All Eligible patients treated in Arm A (standard risk MLL-G).</population>
          <units>percentage probability</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.67" lower_limit="79.45" upper_limit="93.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Group 1: Study Entry to end-Induction (5 weeks). Other Groups: Start of Induction Intensification (Week 6) through 10 years post study enrollment.</time_frame>
      <desc>Adverse event reporting is collected routinely using case report forms. SAE field contains NCI Common Terminology Criteria for Adverse Events (CTCAEs) submitted via expedited reporting (NCI AdEERs / CAeRs). The AE field contains grade 3 and higher CTCAEs reported on study excluding those that were reported as SAEs. Ineligible patients are excluded from reporting of adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Induction (All Patients)</title>
          <description>All Patients for Induction (not assigned)</description>
        </group>
        <group group_id="E2">
          <title>Post Induction (Follow-up Only)</title>
          <description>Post-Induction patients that did not receive therapy</description>
        </group>
        <group group_id="E3">
          <title>Arm A (Standard Risk MLL-G)</title>
          <description>Population Description: Eligible patients with MLL-G (germline, or non-rearranged)
Asparaginase: Given IV, IM, or PO
Cyclophosphamide: Given IV
Cytarabine: Given IV or IT
Daunorubicin Hydrochloride: Given IV
Dexamethasone: Given IV or PO
Etoposide: Given IV
Filgrastim: Given IV or SC
Laboratory Biomarker Analysis: Correlative studies
Leucovorin Calcium: Given IV
Mercaptopurine: Given PO
Methotrexate: Given IV, IT, or PO
Methylprednisolone: Given IV
Pegaspargase: Given IM
Pharmacological Study: Correlative studies
Prednisone: Given PO
Therapeutic Hydrocortisone: Given IT
Vincristine Sulfate: Given IV</description>
        </group>
        <group group_id="E4">
          <title>Arm B (IR/HR MLL-R Chemotherapy)</title>
          <description>Population Description: Eligible patients with MLL-R (rearranged). Considered Intermediate Risk (IR) if age &gt;= 90 days at diagnosis and High Risk (HR) if age &lt; 90 days at diagnosis.
Asparaginase: Given IV, IM, or PO
Cyclophosphamide: Given IV
Cytarabine: Given IV or IT
Daunorubicin Hydrochloride: Given IV
Dexamethasone: Given IV or PO
Etoposide: Given IV
Filgrastim: Given IV or SC
Laboratory Biomarker Analysis: Correlative studies
Leucovorin Calcium: Given IV
Mercaptopurine: Given PO
Methotrexate: Given IV, IT, or PO
Methylprednisolone: Given IV
Pegaspargase: Given IM
Pharmacological Study: Correlative studies
Prednisone: Given PO
Therapeutic Hydrocortisone: Given IT
Vincristine Sulfate: Given IV</description>
        </group>
        <group group_id="E5">
          <title>Arm C (Safety/ Dose Level 1)</title>
          <description>Arm C, IR/HR MLL-R chemotherapy and lestaurtinib at Dose Level 1 (DL1) (HR: 3.5 mg/kg/day; SR: 4 mg/kg/day)</description>
        </group>
        <group group_id="E6">
          <title>Arm C (Safety/ Dose Level 2)</title>
          <description>Arm C, IR/HR MLL-R chemotherapy and lestaurtinib at Dose Level 2 (DL2) (HR: 4.25 mg/kg/day; SR: 5 mg/kg/day)</description>
        </group>
        <group group_id="E7">
          <title>Arm C (Efficacy/ Dose Level 2)</title>
          <description>Arm C, IR/HR MLL-R chemotherapy and lestaurtinib at Dose Level 2 (DL2)-Efficacy (HR: 4.25 mg/kg/day; SR: 5 mg/kg/day)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCv4</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="28" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="41" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" events="5" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Blood and lymphatic system disorders - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="7" subjects_affected="6" subjects_at_risk="11"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" events="42" subjects_affected="22" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hemolytic uremic syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Thrombotic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Heart failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Left ventricular systolic dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="3" subjects_affected="2" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="6" subjects_affected="3" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="9" subjects_affected="5" subjects_at_risk="11"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E7" events="14" subjects_affected="11" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Gastric hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders - Other, specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Gastrointestinal fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E7" events="11" subjects_affected="9" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Small intestinal perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Typhlitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E7" events="4" subjects_affected="3" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>General disorders and administration site conditions - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Immune system disorders - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Anorectal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Bronchial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E7" events="6" subjects_affected="6" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Endocarditis infective</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hepatic infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Infections and infestations - Other, specify</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E5" events="22" subjects_affected="6" subjects_at_risk="11"/>
                <counts group_id="E6" events="9" subjects_affected="5" subjects_at_risk="11"/>
                <counts group_id="E7" events="43" subjects_affected="23" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Mucosal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Peritoneal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" events="14" subjects_affected="11" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Small intestine infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, poisoning and procedural complications - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Vascular access complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="12" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E6" events="4" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" events="16" subjects_affected="10" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="4" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" events="9" subjects_affected="8" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Fibrinogen decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>GGT increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Investigations - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E7" events="10" subjects_affected="7" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E7" events="6" subjects_affected="3" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E7" events="5" subjects_affected="2" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E7" events="9" subjects_affected="6" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="6" subjects_affected="5" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" events="4" subjects_affected="3" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" events="6" subjects_affected="6" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Treatment related secondary malignancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Abducens nerve disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Cognitive disturbance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Oculomotor nerve disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric disorders - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adult respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Apnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="5" subjects_affected="4" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders - Other, specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="3" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Skin ulceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical and medical procedures - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Visceral arterial ischemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCv4</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="181" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="59" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="54" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="55" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="7" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E4" events="7" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" events="7" subjects_affected="5" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Blood and lymphatic system disorders - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="32" subjects_affected="31" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="58" subjects_affected="34" subjects_at_risk="60"/>
                <counts group_id="E4" events="69" subjects_affected="32" subjects_at_risk="54"/>
                <counts group_id="E5" events="9" subjects_affected="6" subjects_at_risk="11"/>
                <counts group_id="E6" events="13" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E7" events="40" subjects_affected="26" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Cardiac disorders - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Eye disorders - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Anal mucositis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Anal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="21" subjects_affected="15" subjects_at_risk="60"/>
                <counts group_id="E4" events="24" subjects_affected="14" subjects_at_risk="54"/>
                <counts group_id="E5" events="5" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" events="28" subjects_affected="16" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Gastric hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="46" subjects_affected="35" subjects_at_risk="60"/>
                <counts group_id="E4" events="29" subjects_affected="24" subjects_at_risk="54"/>
                <counts group_id="E5" events="9" subjects_affected="6" subjects_at_risk="11"/>
                <counts group_id="E6" events="10" subjects_affected="5" subjects_at_risk="11"/>
                <counts group_id="E7" events="30" subjects_affected="24" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Oral hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Rectal mucositis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Small intestinal mucositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="54"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Edema face</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="12" subjects_affected="9" subjects_at_risk="60"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="54"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>General disorders and administration site conditions - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Anaphylaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Immune system disorders - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anorectal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Bladder infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Bronchial infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="20" subjects_affected="13" subjects_at_risk="60"/>
                <counts group_id="E4" events="21" subjects_affected="12" subjects_at_risk="54"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E6" events="3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" events="10" subjects_affected="8" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Endocarditis infective</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="3" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E4" events="8" subjects_affected="7" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Infections and infestations - Other, specify</sub_title>
                <counts group_id="E1" events="66" subjects_affected="52" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="66" subjects_affected="32" subjects_at_risk="60"/>
                <counts group_id="E4" events="116" subjects_affected="36" subjects_at_risk="54"/>
                <counts group_id="E5" events="18" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E6" events="11" subjects_affected="8" subjects_at_risk="11"/>
                <counts group_id="E7" events="39" subjects_affected="19" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E4" events="11" subjects_affected="7" subjects_at_risk="54"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" events="6" subjects_affected="5" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Mucosal infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" events="5" subjects_affected="4" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Penile infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Rash pustular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Scrotal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E4" events="15" subjects_affected="10" subjects_at_risk="54"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="7" subjects_affected="5" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="60"/>
                <counts group_id="E4" events="9" subjects_affected="7" subjects_at_risk="54"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Small intestine infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="9" subjects_affected="7" subjects_at_risk="60"/>
                <counts group_id="E4" events="15" subjects_affected="10" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" events="6" subjects_affected="6" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="9" subjects_affected="7" subjects_at_risk="60"/>
                <counts group_id="E4" events="30" subjects_affected="21" subjects_at_risk="54"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E7" events="14" subjects_affected="13" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Vulval infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Intraoperative hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Vascular access complication</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Wound complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="94" subjects_affected="42" subjects_at_risk="60"/>
                <counts group_id="E4" events="84" subjects_affected="35" subjects_at_risk="54"/>
                <counts group_id="E5" events="32" subjects_affected="8" subjects_at_risk="11"/>
                <counts group_id="E6" events="12" subjects_affected="7" subjects_at_risk="11"/>
                <counts group_id="E7" events="57" subjects_affected="30" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="52" subjects_affected="34" subjects_at_risk="60"/>
                <counts group_id="E4" events="59" subjects_affected="28" subjects_at_risk="54"/>
                <counts group_id="E5" events="11" subjects_affected="5" subjects_at_risk="11"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E7" events="31" subjects_affected="21" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>GGT increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="7" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E5" events="7" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="7" subjects_affected="3" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Investigations - Other, specify</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" events="4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="76" subjects_affected="74" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="62" subjects_affected="29" subjects_at_risk="60"/>
                <counts group_id="E4" events="45" subjects_affected="26" subjects_at_risk="54"/>
                <counts group_id="E5" events="15" subjects_affected="9" subjects_at_risk="11"/>
                <counts group_id="E6" events="8" subjects_affected="5" subjects_at_risk="11"/>
                <counts group_id="E7" events="48" subjects_affected="26" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="13" subjects_affected="9" subjects_at_risk="60"/>
                <counts group_id="E4" events="24" subjects_affected="16" subjects_at_risk="54"/>
                <counts group_id="E5" events="8" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E6" events="5" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E7" events="18" subjects_affected="12" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Urine output decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="9" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E4" events="12" subjects_affected="7" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="19" subjects_affected="14" subjects_at_risk="60"/>
                <counts group_id="E4" events="13" subjects_affected="9" subjects_at_risk="54"/>
                <counts group_id="E5" events="5" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" events="16" subjects_affected="8" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="28" subjects_affected="13" subjects_at_risk="60"/>
                <counts group_id="E4" events="31" subjects_affected="15" subjects_at_risk="54"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E6" events="5" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E7" events="29" subjects_affected="9" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="10" subjects_affected="8" subjects_at_risk="60"/>
                <counts group_id="E4" events="16" subjects_affected="9" subjects_at_risk="54"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E4" events="17" subjects_affected="9" subjects_at_risk="54"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E7" events="8" subjects_affected="7" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="6" subjects_affected="5" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E4" events="5" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E7" events="6" subjects_affected="5" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E5" events="5" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="8" subjects_affected="7" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="36" subjects_affected="35" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="37" subjects_affected="20" subjects_at_risk="60"/>
                <counts group_id="E4" events="41" subjects_affected="14" subjects_at_risk="54"/>
                <counts group_id="E5" events="16" subjects_affected="6" subjects_at_risk="11"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E7" events="37" subjects_affected="22" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="3" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="8" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E4" events="9" subjects_affected="8" subjects_at_risk="54"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" events="3" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Metabolism and nutrition disorders - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Muscle weakness trunk</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Leukemia secondary to oncology chemotherapy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Intracranial hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Nervous system disorders - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="3" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Renal and urinary disorders - Other, specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Penile pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adult respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="8" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E4" events="5" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Laryngeal mucositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pharyngeal mucositis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pulmonary edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="7" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Sinus disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Stridor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Periorbital edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders - Other, specify</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E4" events="6" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Skin induration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Skin ulceration</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="10" subjects_affected="8" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical and medical procedures - Other, specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" events="8" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Vascular disorders - Other, specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Must obtain sponsor approval.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Data was and never will be collected for Outcome Measure #4, 5, 12, and 13.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Results Reporting Coordinator</name_or_title>
      <organization>Children's Oncology Group</organization>
      <phone>626-447-0064</phone>
      <email>resultsreportingcoordinator@childrensoncologygroup.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

